DK3388111T3 - Organoarsenforbindelse til behandlingen af kræft - Google Patents

Organoarsenforbindelse til behandlingen af kræft Download PDF

Info

Publication number
DK3388111T3
DK3388111T3 DK18174817.9T DK18174817T DK3388111T3 DK 3388111 T3 DK3388111 T3 DK 3388111T3 DK 18174817 T DK18174817 T DK 18174817T DK 3388111 T3 DK3388111 T3 DK 3388111T3
Authority
DK
Denmark
Prior art keywords
organous
cancer
link
treatment
organous link
Prior art date
Application number
DK18174817.9T
Other languages
Danish (da)
English (en)
Inventor
Brian Eric Schwartz
Jonathan Lewis
Philip B Komarnitsky
Original Assignee
Solasia Pharma K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solasia Pharma K K filed Critical Solasia Pharma K K
Application granted granted Critical
Publication of DK3388111T3 publication Critical patent/DK3388111T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK18174817.9T 2008-08-20 2009-08-14 Organoarsenforbindelse til behandlingen af kræft DK3388111T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18951108P 2008-08-20 2008-08-20
EP09808635.8A EP2321012B1 (en) 2008-08-20 2009-08-14 Organoarsenic compounds and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3388111T3 true DK3388111T3 (da) 2021-12-06

Family

ID=41707414

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18174817.9T DK3388111T3 (da) 2008-08-20 2009-08-14 Organoarsenforbindelse til behandlingen af kræft
DK09808635.8T DK2321012T3 (en) 2008-08-20 2009-08-14 ORGANIC RELATIONS AND PROCEDURES FOR TREATING CANCER

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09808635.8T DK2321012T3 (en) 2008-08-20 2009-08-14 ORGANIC RELATIONS AND PROCEDURES FOR TREATING CANCER

Country Status (19)

Country Link
US (4) US20110269697A1 (enExample)
EP (2) EP3388111B1 (enExample)
JP (5) JP5933896B2 (enExample)
KR (3) KR20110058818A (enExample)
CN (2) CN102149432A (enExample)
AU (1) AU2009282972A1 (enExample)
BR (1) BRPI0918407A2 (enExample)
CA (1) CA2734650A1 (enExample)
DK (2) DK3388111T3 (enExample)
ES (2) ES2901426T3 (enExample)
HK (1) HK1212218A1 (enExample)
IL (1) IL211153A0 (enExample)
MX (1) MX2011001800A (enExample)
NZ (1) NZ591181A (enExample)
PT (2) PT2321012T (enExample)
RU (1) RU2534606C2 (enExample)
SG (3) SG10201810450QA (enExample)
WO (1) WO2010021928A1 (enExample)
ZA (1) ZA201101216B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
CN104151397A (zh) * 2014-07-03 2014-11-19 北京大学 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用
JP6413969B2 (ja) * 2015-07-29 2018-10-31 住友金属鉱山株式会社 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体
WO2019220961A1 (ja) * 2018-05-18 2019-11-21 ソレイジア・ファーマ株式会社 ダリナパルシンのアルカリ金属塩及び/又は無機酸付加塩の結晶型及びその製剤
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US234972A (en) 1880-11-30 William ennis
US761900A (en) 1904-03-05 1904-06-07 Newton Jefferson Norman Flux compound.
US2349729A (en) 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
WO1999018798A1 (en) 1997-10-15 1999-04-22 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
CN1443064A (zh) 2000-04-26 2003-09-17 俄勒冈健康科学大学 施用含硫醇化学保护化合物的方法
DE10132625A1 (de) 2001-07-05 2003-01-23 Oce Printing Systems Gmbh Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten
EP2462932A1 (en) 2002-01-07 2012-06-13 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN104109177A (zh) * 2006-01-13 2014-10-22 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
CA2694987A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
KR20100100835A (ko) * 2007-11-02 2010-09-15 지오팜 온콜로지 인코포레이티드 유기 비소제와의 병용 요법
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders

Also Published As

Publication number Publication date
US11324714B2 (en) 2022-05-10
DK2321012T3 (en) 2018-12-03
SG10201810449XA (en) 2018-12-28
EP3388111B1 (en) 2021-09-29
US20210038556A1 (en) 2021-02-11
SG10201403869TA (en) 2014-10-30
CN102149432A (zh) 2011-08-10
JP2017002081A (ja) 2017-01-05
JP5933896B2 (ja) 2016-06-15
WO2010021928A1 (en) 2010-02-25
US10842769B2 (en) 2020-11-24
ZA201101216B (en) 2011-10-26
JP6315841B2 (ja) 2018-04-25
HK1212218A1 (en) 2016-06-10
IL211153A0 (en) 2011-04-28
MX2011001800A (es) 2011-04-04
CN104800828A (zh) 2015-07-29
EP2321012A4 (en) 2011-10-05
US20210038557A1 (en) 2021-02-11
EP3388111A1 (en) 2018-10-17
SG10201810450QA (en) 2018-12-28
KR20170103023A (ko) 2017-09-12
CA2734650A1 (en) 2010-02-25
KR20180103194A (ko) 2018-09-18
US20110269697A1 (en) 2011-11-03
JP2012500271A (ja) 2012-01-05
RU2534606C2 (ru) 2014-11-27
PT2321012T (pt) 2019-01-11
JP2014148552A (ja) 2014-08-21
JP2015120755A (ja) 2015-07-02
KR20110058818A (ko) 2011-06-01
ES2703740T3 (es) 2019-03-12
EP2321012A1 (en) 2011-05-18
HK1254607A1 (en) 2019-07-26
BRPI0918407A2 (pt) 2015-11-24
JP2018039853A (ja) 2018-03-15
PT3388111T (pt) 2021-12-23
EP2321012B1 (en) 2018-10-10
US11324713B2 (en) 2022-05-10
AU2009282972A1 (en) 2010-02-25
US20150231107A1 (en) 2015-08-20
RU2011110392A (ru) 2012-09-27
JP5976036B2 (ja) 2016-08-23
NZ591181A (en) 2012-09-28
ES2901426T3 (es) 2022-03-22

Similar Documents

Publication Publication Date Title
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0810206A2 (pt) Método de tratar câncer
BR112012005594A2 (pt) tratamento de câncer
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
BRPI0910854A2 (pt) métodos de tratamento
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK2121139T3 (da) Formulations for cancer treatment
DK2330887T3 (da) Behandlingsindretning
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2173831T3 (da) Brøndbehandling
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DK2310613T3 (da) Forbedret brudled til stigrør
BRPI0922884A2 (pt) compostos para tratamento de câncer
EP2283862A4 (en) ANTITUMOR AGENT
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme